Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …

The vaccine and drug discovery responses to COVID-19 have worked far better than could
have been imagined. Yet by the end of 2021, more than 5 million people had died, and the …

The persistent COVID-19 pandemic since 2020 has brought an enormous public health
burden to the global society and is accompanied by various evolution of the virus genome …

Since the first monoclonal antibody drug, muromonab-CD3, was approved for marketing in
1986, 165 antibody drugs have been approved or are under regulatory review worldwide …

Many therapeutic antibodies (Abs) and mRNA vaccines, both targeting SARS-CoV-2 spike
protein (S-protein), have been developed and approved in order to combat the ongoing …

Antibody engineering has developed into a wide-reaching field, impacting a multitude of
industries, most notably healthcare and diagnostics. The seminal work on developing the …

Multiple variants of SARS-CoV-2 have emerged and are now prevalent at the global level.
Currently designated variants of concern (VOCs) are B. 1.1. 7, B1. 351, P. 1, B. 1.617. 2 …

Since 2019, the novel coronavirus (SARS-COV-2) disease (COVID-19) has caused a
worldwide epidemic. Anti-coronavirus peptides (ACovPs), a type of antimicrobial peptides …

The development of neutralizing antibodies (nAbs) is an important strategy to tackle the
Omicron variant. Omicron N-terminal domain (NTD) mutations including A67V, G142D, and …

The drug discovery and research for an anti-COVID-19 drug has been ongoing despite
repurposed drugs in the market. Over time, these drugs were discontinued due to side …